Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - Safety and efficacy in 1,032 patients with hematologic malignancy

Hidesaku Asakura, Hoyu Takahashi, Hajime Tsuji, Tadashi Matsushita, Hideyuki Ninomiya, Goichi Honda, Jun Mimuro, Yutaka Eguchi, Isao Kitajima, Yoichi Sakata
  • Thrombosis Research, March 2014, Elsevier
  • DOI: 10.1016/j.thromres.2013.12.033

Thrombomodulin in 1,032 DIC patients with hematologic malignancy.

What is it about?

TM is an ideal treatment for patients with DIC based upon hematologic malignancy.

Why is it important?

Coagulation tests were significantly improved after TM treatment even in subjects whose clinical course of underlying disease was assessed as unchanged or exacerbated.

Read Publication

http://dx.doi.org/10.1016/j.thromres.2013.12.033

The following have contributed to this page: Hidesaku Asakura